Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 156 participants.

Also called NCT02002221

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 156 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02002221
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02002221. Randomized; triple masking; primary purpose treatment. Start 2013-12 (registry gives no type); primary completion 2015-02 (actual). Results posted on 2016-03-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Drug)
Vildagliptin (LAF237)
Intervention (Drug)
Placebo
Intervention (Drug)
Insulin
Intervention (Drug)
Metformin
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct02002221
Content hash
4305ac8e19013e792990d7a5813bfedef3abc8ce59e95a6ad13abc30ee598daf